ZnPT has been reported to target cancer cells by increasing intracellular Zn2+ concentration, followed by ERK activation, reactive oxygen species generation [28], loss of NF-κB expression and its target genes in AML cells [17], activation of p53 and its dependent genes Puma and Bax associated with loss of mitochondrial membrane potential [29]. The gene discussed is BAX; the disease is acute myeloid leukemia.